
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
As biological products are being investigated as treatment modalities, measures to ensure safety and quality from microbiological contamination becomes imperative.






